PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development
Open Access
- 15 April 2025
- journal article
- basic and-translational-cancer-immunology
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (4) , e011366
Abstract
Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remain challenging. Methods Over 10,000 raw mass spectrometry (MS) files from over 3,000 tissue samples were analyzed, summing to approximately seven terabytes of data. The raw MS data were processed using the standardized and open-source nf-core pipelines MHCquant2 and epitopeprediction, providing a uniform procedure for data handling. A global false discovery rate was applied to minimize false-positive identifications. Results Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes >6.6 million HLA class I and >3.4 million HLA class II peptides from over 40 tissue types and cancer entities. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens (TAAs) as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent TAAs matching the immunopeptidome of the individual patient’s tumor and a neoepitope-based vaccine matching the mutational profile of a patient with cancer. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these patients with advanced cancer. Conclusion The PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.Keywords
All Related Versions
Funding Information
- Applied Clinical Research program
- Deutsche Forschungsgemeinschaft (DFG Grant WA4608/1-2)
- Deutsche Forschungsgemeinschaft under Germany‘s Excellence Strategy (EXC2180)
- Deutsche Forschungsgemeinschaft under Germany‘s Excellence Strategy (EXC2180-390900677)
- Deutsche Krebshilfe (70114948)
- José Carreras Leukämie-Stiftung (Grant DJCLS 05 R/2017)
- Zentrum für Personalisierte Medizin
- Deutschen Konsortium für Translationale Krebsforschung
- Wilhelm Sander Stiftung (Grant 2016.177.3)
- Ernst Jung Prize for Medicine
- Landesforschungspreis of Baden-Württemberg
- ForTra gGmbH of the Else Kröner Fresenius Stiftung, Translatorik Programm (Grant 2022_EKTP03)
This publication has 72 references indexed in Scilit:
- MS2Rescore: Data-Driven Rescoring Dramatically Boosts Immunopeptide Identification RatesMolecular & Cellular Proteomics, 2022
- caAtlas: An immunopeptidome atlas of human canceriScience, 2021
- The Choice of Search Engine Affects Sequencing Depth and HLA Class I Allele-Specific Peptide RepertoiresMolecular & Cellular Proteomics, 2021
- MHCquant: Automated and Reproducible Data Analysis for ImmunopeptidomicsJournal of Proteome Research, 2019
- Purification and Identification of Naturally Presented MHC Class I and II Ligands2019
- Driver Fusions and Their Implications in the Development and Treatment of Human CancersCell Reports, 2018
- A Case for a Human Immuno-Peptidome Project ConsortiumImmunity, 2017
- Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patientJournal of Hepatology, 2016
- Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potentialLeukemia, 2015
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencingNature, 2014